Supportive Leukemias / Lymphomas Studies

Non-therapeutic protocols address such issues as side effects or long-term effects of therapy, quality of life, making testing easier on the children, prevention of pain, and issues related to nutrition and stress. There are also tissue and blood banking protocols for laboratory researchers who are studying diseases and searching for underlying causes and cures. The research at St. Jude is designed to include all aspects related to the care of sick children and their families.

St. Jude Clinical Trials

DSCOG: Learning, Behavior and Social Skills in Survivors of Childhood Leukemia with Down syndrome

Diseases Treated:

Leukemia

Eligibility:

This is a non-therapeutic clinical trial that is open only to patients who were treated at St. Jude Children’s Research Hospital since 1980 and are currently followed at the hospital.

  • St. Jude Children’s Research Hospital patient with acute leukemia (i.e., ALL or AML)
  • Trisomy 21 Down syndrome diagnosis
  • Completed all cancer therapy at St. Jude since 1980 and at least six months prior to study visit
  • English as the primary language
View Trial

LiSTENING: Learning in Story: Elicited Narrative Informs Navigating Genetics

Eligibility:

This is a non-therapeutic clinical trial open to St. Jude patients only.

Participants have been pre-identified by the primary care team as an English-speaking, four-member family unit diagnosed with TP53 mutation.

View Trial

Collaborative Clinical Trials

NCBP01: Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

Diseases Treated:

Leukemia and other blood diseases

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • Participant is receiving an allogeneic hematopoietic stem cell (HSC) transplant at St. Jude Children's Research Hospital using an unlicensed cord blood unit (CBU).
  • Participant may be of any age and either gender.
  • Participant has a medical disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.
  • Participant is receiving HPC-CORD BLOOD product manufactured by NCBP (at least one, if the graft contains more than one units).
View Trial